<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="study:id" content="liso-cel-post-cart-monitoring-kamdar-lunning">
    <meta name="study:title" content="PS1916 - Optimizing post-chimeric antigen receptor T cell monitoring: Evidence across lisocabtagene maraleucel pivotal clinical trials and real-world experience">
    <meta name="study:fileName" content="Abstracts/LISO-CEL-POST-CART-MONITORING-LUNNING-PS1916.html">
    <meta name="study:cancerTypes" content="LBCL,FL,B-NHL">
    <meta name="study:lineOfTherapy" content="2L+">
    <meta name="study:evidenceType" content="Clinical trial">
    <meta name="study:drugs" content="Lisocabtagene maraleucel,CAR-T cell therapy">

    <title>PS1916: Liso-cel Post-CAR T Monitoring (Kamdar/Lunning) - SOBI Themed</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://d3js.org/d3.v7.min.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="abstract_styles.css"> <style>
        /* Lightbox styles */
        .lightbox {
            display: none;
            position: fixed;
            z-index: 999;
            padding-top: 50px;
            left: 0;
            top: 0;
            width: 100%;
            height: 100%;
            overflow: auto;
            background-color: rgba(0,0,0,0.9);
        }
        .lightbox-content {
            margin: auto;
            display: block;
            width: 80%;
            max-width: 800px;
            max-height: 80vh;
        }
        .lightbox-caption {
            margin: auto;
            display: block;
            width: 80%;
            max-width: 700px;
            text-align: center;
            color: #ccc;
            padding: 10px 0;
            height: 50px;
        }
        .lightbox-close {
            position: absolute;
            top: 15px;
            right: 35px;
            color: #f1f1f1;
            font-size: 40px;
            font-weight: bold;
            transition: 0.3s;
        }
        .lightbox-close:hover,
        .lightbox-close:focus {
            color: #bbb;
            text-decoration: none;
            cursor: pointer;
        }
        .table-image-thumbnail {
            cursor: zoom-in;
            transition: 0.3s;
            max-width: 100%; /* Ensure thumbnail is responsive */
            height: auto;
        }
        .table-image-thumbnail:hover {opacity: 0.7;}
    </style>
</head>
<body class="abstract-page-body">
    <div class="slide-container">
        <div class="visual-abstract-container">
            <h2 class="visual-abstract-title">Visual Summary: PS1916 - Optimizing Post Liso-cel CAR T Monitoring (Pivotal Trials & RWE)</h2>
            <div class="visual-abstract-grid">
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path d="M12 6.096c-1.058 0-2.02.468-2.704 1.248-.685.78-.996 1.788-.996 2.856s.311 2.076.996 2.856C9.98 13.84 10.942 14.31 12 14.31s2.02-.468 2.704-1.248.996-1.788.996 2.856-.311-2.076-.996-2.856C14.02 6.564 13.058 6.096 12 6.096zM12 12.81c-.53 0-1.008-.222-1.352-.588-.344-.366-.528-.852-.528-1.422s.184-1.056.528-1.422C10.992 9.012 11.47 8.79 12 8.79s1.008.222 1.352.588.528.852.528 1.422-.184-1.056-.528 1.422C13.008 12.588 12.53 12.81 12 12.81zm6.708 3.672A7.47 7.47 0 0012.024 15c-1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 004.5 19.686V21h15v-1.314a4.476 4.476 0 00-3.792-3.624zM6.024 16.56c.84-.468 1.848-.768 2.904-.924A5.928 5.928 0 0112.024 15a5.928 5.928 0 013.096.636c1.056.156 2.064.456 2.904.924A2.988 2.988 0 0019.5 18.018V19.5h-15v-1.482a2.988 2.988 0 001.524-2.458zM4.5 7.032c0-1.068.312-2.076.996-2.856S7.2 3 8.256 3A7.47 7.47 0 0112.024 1.5c1.404 0 2.706.39 3.816 1.056A4.476 4.476 0 0119.5 6.186V7.5H4.5v-.468zM18 4.56c-.84.468-1.848.768-2.904-.924A5.928 5.928 0 0012.024 6a5.928 5.928 0 00-3.096.636 7.524 7.524 0 00-2.904.924A2.988 2.988 0 014.5 7.482V6H3V4.5A1.5 1.5 0 014.5 3h15A1.5 1.5 0 0121 4.5V6h-1.5v1.482a2.988 2.988 0 01-1.524 2.458L18 4.56z" />
                    </svg>
                    <h4>Population & Aim (N=1579)</h4>
                    <p>Pts treated with Liso-cel in pivotal trials (N=702; LBCL, CLL/SLL, MCL, FL) or CIBMTR Registry (N=877; R/R LBCL). Aim: Report CRS/ICANS timing to inform safety monitoring.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path fill-rule="evenodd" d="M10.5 3.75a.75.75 0 01.75-.75h1.5a.75.75 0 01.75.75V4.5h3A2.25 2.25 0 0118.75 6.75v1.5a2.25 2.25 0 01-2.25 2.25H15.5V12h1.25a.75.75 0 010 1.5H15.5v1.5h.75a.75.75 0 010 1.5H15.5v1.5H18a.75.75 0 010 1.5h-2.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0v-3A2.25 2.25 0 016 14.25v-1.5A2.25 2.25 0 018.25 10.5H9.5V9H8.25A2.25 2.25 0 016 6.75v-1.5A2.25 2.25 0 018.25 3H10.5V3.75zm-1.5 6.75h6V6.75H9V10.5z" clip-rule="evenodd" />
                    </svg>
                    <h4>Methods (Data Sources)</h4>
                    <p>Combined data from 5 Liso-cel pivotal trials & CIBMTR Registry. Assessed CRS/ICANS incidence, onset, grade, duration.</p>
                </div>
                <div class="visual-abstract-item">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M3.75 3A.75.75 0 003 3.75v16.5a.75.75 0 00.75.75h16.5a.75.75 0 00.75-.75V3.75a.75.75 0 00-.75-.75H3.75zm14.25 1.5H6v13.5h12V4.5zm-10.5 3a.75.75 0 000 1.5h9a.75.75 0 000-1.5h-9zm0 3.75a.75.75 0 000 1.5h9a.75.75 0 000-1.5h-9zm0 3.75a.75.75 0 000 1.5H9a.75.75 0 000-1.5H6z" clip-rule="evenodd" />
                    </svg>
                    <h4>Key Findings (CRS/ICANS Onset & Severity)</h4>
                    <p>Trials (N=702): CRS 54% (G≥3 1%), ICANS 31% (G≥3 5%). CIBMTR (N=877): CRS 49% (G≥3 3%), ICANS 27% (G≥3 7%). Majority onset ≤2wks.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M12 2.25c-5.385 0-9.75 4.365-9.75 9.75s4.365 9.75 9.75 9.75 9.75-4.365 9.75-9.75S17.385 2.25 12 2.25zm-.092 14.444a.75.75 0 01-.092 0l-3.75-3.75a.75.75 0 111.06-1.06L12 14.813l3.182-3.182a.75.75 0 111.06 1.06l-3.75 3.75a.75.75 0 01-.53.22z" clip-rule="evenodd" />
                    </svg>
                    <h4>Conclusion</h4>
                    <p>Most CRS/ICANS events with Liso-cel occur ≤2 weeks post-infusion & are not severe. Late onsets (>Day 15) rare, mostly low grade & resolved.</p>
                </div>
            </div>
        </div>

        <div class="text-center mb-8">
            <h1 class="abstract-header-title">PS1916 - Optimizing post-chimeric antigen receptor T cell monitoring: Evidence across lisocabtagene maraleucel pivotal clinical trials and real-world experience</h1>
            <p class="abstract-sub-header">Manali Kamdar, Mazyar Shadman, Sairah Ahmed, et al.</p>
            <p class="abstract-meta-info mt-2">EHA 2025 Congress | Abstract #PS1916 | Poster Presentation</p>
        </div>

        <div class="grid md:grid-cols-2 gap-x-8 gap-y-6">
            <div> <div class="abstract-card">
                    <h2 class="abstract-section-title">Background</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>CAR T cell therapies show remarkable efficacy in B-cell Non-Hodgkin Lymphoma (NHL).</li>
                        <li>Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) are associated toxicities with implications for safety monitoring.</li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Aims</h2>
                    <p class="text-sm mb-1">To report CRS and ICANS timing in 1579 patients treated with lisocabtagene maraleucel (liso-cel) in pivotal clinical trials across various B-cell NHL indications or in the standard of care (SOC) setting, to inform safety monitoring requirements for these events.</p>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Methods & Data Sources</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 mb-3 pl-2">
                        <li><strong>Pivotal Clinical Trials (N=702):</strong>
                            <ul class="list-circle list-inside ml-4">
                                <li>Data from TRANSCEND NHL 001, TRANSCEND CLL 004, TRANSFORM, PILOT, and TRANSCEND FL.</li>
                                <li>Indications: R/R Large B-Cell Lymphoma (LBCL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Mantle Cell Lymphoma (MCL), and Follicular Lymphoma (FL).</li>
                            </ul>
                        </li>
                        <li><strong>CIBMTR Registry (N=877):</strong>
                            <ul class="list-circle list-inside ml-4">
                                <li>Patients who received commercial liso-cel for R/R LBCL and had ≥1 assessment post-infusion.</li>
                            </ul>
                        </li>
                        <li><strong>Outcomes Assessed:</strong> Incidence, onset, grade, and duration of CRS and ICANS.</li>
                    </ul>
                     <div class="study-design-schema">
                        <h3 class="schema-title">Liso-cel CRS/ICANS Timing Analysis</h3>
                        <div class="schema-enrollment">
                            <strong>Total Patients (N=1579) Treated with Liso-cel</strong>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-phase-group justify-around">
                            <div class="schema-phase cohort-a" style="flex-basis: 48%;">
                                <strong>Pivotal Clinical Trials (N=702)</strong>
                                <span>(TRANSCEND NHL 001, CLL 004, TRANSFORM, PILOT, TRANSCEND FL)</span>
                                <span>Indications: R/R LBCL, CLL/SLL, MCL, FL</span>
                            </div>
                             <div class="schema-phase cohort-b" style="flex-basis: 48%;">
                                <strong>CIBMTR Registry (N=877)</strong>
                                <span>Commercial Liso-cel for R/R LBCL</span>
                                <span>(SOC Setting)</span>
                            </div>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-assessment-points">
                           <span>CRS & ICANS Characterization</span>
                           <span>(Incidence, Onset, Grade, Duration)</span>
                           <span>Goal: Inform Safety Monitoring Requirements</span>
                        </div>
                    </div>
                </div>
            </div> <div> <div class="abstract-card">
                    <h2 class="abstract-section-title">Results: CRS and ICANS Characteristics</h2>
                    <p class="text-sm mb-2">Details on CRS and ICANS are summarized in the table below.</p>
                    <div class="abstract-card mt-4 table-container-card">
                        <h3 class="text-md font-semibold mb-2 text-center" style="color: var(--sobi-dark-blue);">Table: CRS and ICANS in liso-cel-treated patients</h3>
                        <img id="lisoCelTableThumbnail" src="uploaded:image_6768d1.jpg-c9576fce-eb23-427a-bb5a-e6872dd182df" alt="Table of CRS and ICANS in liso-cel-treated patients" class="table-image-thumbnail mx-auto rounded-lg shadow-md">
                        <p class="text-xs text-center mt-2 italic">Table: CRS and ICANS in liso-cel-treated patients. Click image to enlarge.</p>
                    </div>

                    <div id="lisoCelTableLightbox" class="lightbox">
                        <span class="lightbox-close" id="closeLisoCelTableLightbox">&times;</span>
                        <img class="lightbox-content" id="lisoCelTableLightboxImage">
                        <div class="lightbox-caption" id="lisoCelTableLightboxCaption"></div>
                    </div>

                    <p class="text-sm font-semibold mt-3 mb-1">Key Findings from Pivotal Trials (N=702):</p>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li><strong>CRS:</strong> 54% any-grade (46% no CRS). Grade ≥3 at onset: 1%. 98% onset ≤2 weeks. Median duration: 5 days. 7 pts with onset >Day 15 (all Gr 1/2, all resolved).</li>
                        <li><strong>ICANS:</strong> 31% any-grade (69% no ICANS). Grade ≥3 at onset: 5%. 88% onset ≤2 weeks. Median duration: 7 days. 27 pts with onset >Day 15 (20 Gr1, 6 Gr2, 1 Gr3; all resolved except 1 Gr2 leukoencephalopathy).</li>
                    </ul>
                     <p class="text-sm font-semibold mt-3 mb-1">Key Findings from CIBMTR Registry (N=877):</p>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li><strong>CRS:</strong> 49% any-grade (51% no CRS). Grade ≥3: 3%. 97% onset ≤2 weeks. Median duration: 4 days. 15 pts with onset >Day 15 (13 resolved).</li>
                        <li><strong>ICANS:</strong> 27% any-grade (73% no ICANS). Grade ≥3: 7%. For 150 pts with onset date, 95% onset ≤2 weeks. Median duration: 5.5 days. 8 pts with onset >Day 15 (5 resolved).</li>
                    </ul>
                    <p class="text-sm mt-2">Further characterization/management of CRS/ICANS events will be presented.</p>
                </div>
            </div> </div> <div class="abstract-card mt-6">
            <h2 class="abstract-section-title">Summary & Conclusion</h2>
            <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                <li>Data from both liso-cel pivotal clinical trials and the real-world SOC setting (CIBMTR Registry) consistently demonstrate that most CRS and ICANS events occur within 2 weeks after infusion.</li>
                <li>The majority of these events were not severe.</li>
                <li>For the few patients who experienced onset of CRS or ICANS after Day 15, most events were low grade and resolved.</li>
                <li>These findings support current safety monitoring practices for liso-cel and highlight the generally manageable nature of late-onset events.</li>
            </ul>
        </div>
        <div class="abstract-card mt-6">
            <p class="text-xs italic">Sponsor: Bristol Myers Squibb.</p>
        </div>

        <div class="abstract-card mt-6 abbreviations-list">
            <h2 class="abstract-section-title">Abbreviations</h2>
            <p>CAR T, Chimeric Antigen Receptor T cell; CIBMTR, Center for International Blood and Marrow Transplant Research; CLL/SLL, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma; CRS, Cytokine Release Syndrome; FL, Follicular Lymphoma; Gr, Grade; ICANS, Immune Effector Cell-Associated Neurotoxicity Syndrome; LBCL, Large B-Cell Lymphoma; Liso-cel, Lisocabtagene maraleucel; MCL, Mantle Cell Lymphoma; NHL, Non-Hodgkin Lymphoma; Pts, Patients; R/R, Relapsed or Refractory; SOC, Standard of Care.</p>
        </div>

        <div class="abstract-card mt-6 reference-section">
            <h2 class="abstract-section-title">
                Reference
                <button id="copyReferenceBtn" class="copy-reference-button" title="Copy Reference">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor">
                        <path d="M7 3.5A1.5 1.5 0 018.5 2h3.879a1.5 1.5 0 011.06.44l3.122 3.121A1.5 1.5 0 0117 6.621V16.5a1.5 1.5 0 01-1.5 1.5h-7A1.5 1.5 0 017 16.5v-13z" />
                        <path d="M4.5 6A1.5 1.5 0 003 7.5v10A1.5 1.5 0 004.5 19h7a1.5 1.5 0 001.5-1.5v-2.5a.75.75 0 00-1.5 0v2.5a.5.5 0 01-.5.5h-7a.5.5 0 01-.5-.5v-10a.5.5 0 01.5-.5h2.5a.75.75 0 000-1.5H4.5z" />
                    </svg>
                    Copy
                </button>
            </h2>
            <p id="referenceSectionContent">Kamdar M, Shadman M, Ahmed S, et al. Optimizing post-chimeric antigen receptor T cell monitoring: Evidence across lisocabtagene maraleucel pivotal clinical trials and real-world experience. Abstract #PS1916 presented at European Haematology Association (EHA) June 12–15, 2025, Milan, Italy.</p>
        </div>

        <div class="abstract-footer-info">
            <p>EHA 2025 Congress | Abstract #PS1916 | Abstract Release: 05/22/25 | Presentation: 06/14/2025</p>
            <p class="text-xs italic mt-1">© 2025 American Society of Clinical Oncology, Inc. Reused with permission. This abstract was accepted and previously presented at the 2025 ASCO Annual Meeting. All rights reserved.</p>
            <p>For Research & Informational Purposes Only.</p>
        </div>
    </div> <script defer src="abstract_features.js"></script>
    <script>
        // Lightbox JavaScript
        document.addEventListener('DOMContentLoaded', function() {
            const lightbox = document.getElementById('lisoCelTableLightbox');
            const lightboxImg = document.getElementById('lisoCelTableLightboxImage');
            const lightboxCaption = document.getElementById('lisoCelTableLightboxCaption');
            const thumbnail = document.getElementById('lisoCelTableThumbnail');
            const closeBtn = document.getElementById('closeLisoCelTableLightbox');

            if (thumbnail) {
                thumbnail.onclick = function(){
                    lightbox.style.display = "block";
                    lightboxImg.src = this.src;
                    lightboxCaption.innerHTML = this.alt;
                }
            }

            if (closeBtn) {
                closeBtn.onclick = function() {
                    lightbox.style.display = "none";
                }
            }

            // Optional: Close lightbox when clicking outside the image
            if (lightbox) {
                lightbox.onclick = function(event) {
                    if (event.target === lightbox) { // Check if the click is on the overlay itself
                        lightbox.style.display = "none";
                    }
                }
            }
        });
    </script>
</body>
</html>
